Detalhe da pesquisa
1.
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
Neurol Sci
; 44(5): 1515-1532, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36648561
2.
An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.
Value Health
; 25(12): 1977-1985, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35963840
3.
Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment.
Future Oncol
; 18(25): 2843-2856, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35801416
4.
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
BMC Cancer
; 20(1): 1087, 2020 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33172403
5.
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Am J Hematol
; 95(12): 1486-1494, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32804408
6.
The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis.
AIDS Care
; 25(4): 400-14, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-22908886
7.
Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States.
Expert Rev Hematol
; 16(1): 65-74, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36579455
8.
Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
J Med Econ
; 26(1): 494-502, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970763
9.
Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
Mult Scler Relat Disord
; 78: 104881, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556938
10.
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Mult Scler Relat Disord
; 70: 104484, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608538
11.
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
Curr Med Res Opin
; 38(11): 1935-1945, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35975577
12.
Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study.
J Med Econ
; 25(1): 182-192, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35023807
13.
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
J Manag Care Spec Pharm
; 27(10): 1377-1387, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595950
14.
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Clinicoecon Outcomes Res
; 13: 789-800, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531667
15.
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study.
Drugs Real World Outcomes
; 8(2): 187-195, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33565004
16.
A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
J Manag Care Spec Pharm
; 25(4): 449-459, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917078
17.
Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study.
Clin Ther
; 41(5): 866-881.e7, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31030993
18.
Letter--The Authors Respond.
J Manag Care Spec Pharm
; 25(9): 1028-1030, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456500
19.
Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study.
J Clin Anesth
; 55: 33-41, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30594097
20.
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
Am Health Drug Benefits
; 11(1): 39-46, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29692879